Table 2.
Association of RUNX1 and BAALC expression levels depending on rs62527607[GT] genotype and RUNX1 expresser status in the test set and the validation set and in the two sets combined
| High RUNX1 | Test set |
Validation set |
Combined sets |
|||||||
| BAALC expression | Low, n = 74 (%) | High, n = 63 (%) | *P value | Low, n = 23 (%) | High, n = 29 (%) | *P value | Low, n = 97 (%) | High, n = 92 (%) | **P value | |
| Genotype counts | GG | 64 (86) | 35 (56) | 18 (78) | 18 (62) | 82 (85) | 53 (58) | |||
| GT | 8 (11) | 27 (43) | 4 (17) | 11 (38) | 12 (12) | 38 (41) | ||||
| TT | 2 (3) | 1 (2) | 1 (4) | 0 (0) | 3 (3) | 1 (1) | ||||
| GT + TT | 10 (14) | 28 (44) | 1.18 × 10−4 | 5 (22) | 11 (38) | 0.21 | 15 (15) | 39 (42) | 7.97 × 10−5 | |
| OR (95% CI) | 5.12 (2.29,12.24) | 2.20 (0.66, 8.19) | 4.02 (2.05, 8.21) | |||||||
| Low RUNX1 | ||||||||||
| BAALC expression | Low, n = 60 (%) | High, n = 56 (%) | Low, n = 30 (%) | High, n = 22 (%) | Low, n = 90 (%) | High, n = 78 (%) | ||||
| Genotype counts | GG | 44 (73) | 35 (62.5) | 25 (83) | 18 (82) | 69 (77) | 53 (68) | |||
| GT | 12 (20) | 19 (34) | 4 (13) | 4 (18) | 16 (18) | 23 (29) | ||||
| TT | 4 (7) | 2 (3.5) | 1 (3) | 0 (0) | 5 (6) | 2 (3) | ||||
| GT + TT | 16 (27) | 21 (37.5) | 0.21 | 5 (17) | 4 (18) | 0.89 | 21 (23) | 25 (32) | 0.24 | |
Test set, Cancer and Leukemia Group B; validation set, German-Austrian AML Study Group. All P values for genotypes compare GG with GT+TT and are obtained from *univariable or **multivariable logistic regression analyses. CI, confidence interval; OR, odds ratio.